💊 Jubilant Pharmova Q2 FY 2025-26 Results: Strong Growth Momentum in Specialty Pharma and CDMO Businesses
📊 Jubilant Pharmova Q2 FY 2025-26 Financial Snapshot
| Particulars | Q2 FY 2025-26 | Q1 FY 2025-26 | Q2 FY 2024-25 |
|---|---|---|---|
| Revenue (₹ crore) | 1,910 est. | 1,901 | 1,774 |
| EBITDA (₹ crore) | 310 est. | 302 | 311 |
| EBITDA Margin (%) | 16.2 % est. | 15.8 % | 17.5 % |
| Net Profit (₹ crore) | 108 est. | 103 | 103 |
| YoY Revenue Growth (%) | +8 % | +10 % | +5 % |
| Net-Debt/EBITDA (x) | 1.2 x | 1.2 x | 1.1 x |
*Estimates are based on management commentary and available financial disclosures.
🧾 Quarter-on-Quarter and Year-on-Year Performance Review
Jubilant Pharmova’s Q2 FY 2025-26 results highlight steady operational progress and margin recovery, driven by strong demand in the radiopharmaceutical and contract development & manufacturing (CDMO) segments.
On a year-on-year basis, revenue is expected to grow by around 8 %, while profit after tax (PAT) is set to rise modestly due to continued investment spending and new capacity expansion.
Compared to Q1 FY 2025-26, revenue growth remains stable at around 0.5 %, reflecting a consistent business environment amid regulatory and cost challenges.
🔬 Segment-Wise Business Analysis
🔹 1. Radiopharmaceuticals
The Radiopharma business remains a core driver of Jubilant’s global growth. Strong demand for nuclear medicine, diagnostic imaging, and therapeutic products has boosted performance in North America and Europe.
Jubilant’s radiopharmacy network in the U.S. continued to expand its reach, supporting recurring revenues and higher margins. This business now contributes nearly 45 % of consolidated revenue, making it a key pillar of growth for the company.
Management Note: “Our Radiopharma and Allergy Immunotherapy businesses continue to see strong demand, supported by our strategic investments in innovation and customer outreach.”
🔹 2. CDMO & Sterile Injectables
Jubilant’s Contract Development and Manufacturing (CDMO) division saw sequential improvement, backed by higher customer orders and new global contracts.
The Sterile Injectables segment gained traction as new products entered regulated markets, contributing to higher revenue visibility for the next two quarters.
With increased utilization levels in facilities across India and North America, CDMO revenue is expected to post double-digit growth for the full year FY 2025-26.
🔹 3. CRDMO and Discovery Services
The Contract Research, Development, and Manufacturing Organization (CRDMO) segment continues to strengthen its order book. Jubilant has signed multiple projects with leading global pharmaceutical companies, particularly in drug discovery, chemistry, and biologics.
These partnerships position the company as a preferred outsourcing partner, ensuring recurring business from long-term clients.
🔹 4. Generics and Specialty Pharmaceuticals
The Generics business remained stable, though price pressure in regulated markets slightly offset volume growth.
The focus is gradually shifting toward complex generics and specialty injectables, which offer better margins and less competition.
This strategic shift is part of Jubilant’s ongoing business transformation aimed at reducing dependence on commoditized products.
💰 Margin and Profitability Analysis
Jubilant Pharmova’s EBITDA margin improved 40 bps QoQ to around 16.2 %, supported by:
Lower raw-material costs
Improved product mix
Higher operating efficiency in CDMO and Radiopharma businesses
However, ongoing capex and R&D spending (especially in sterile injectables and discovery research) slightly constrained profit growth in the short term.
Net Profit is expected to be around ₹ 108 crore, marking an increase of nearly 5 % QoQ and 5 % YoY — consistent with the company’s steady, investment-led growth strategy.
🏗️ Balance Sheet and Debt Position
As of Q2 FY 2025-26, Jubilant Pharmova’s net-debt-to-EBITDA ratio remained stable at 1.2 x, reflecting disciplined financial management despite ongoing capital expenditure.
The company continues to invest in expanding its sterile injectable and CRDMO capacities. These investments are expected to yield significant returns in FY 2026-27 and beyond.
🧩 Operational Highlights
Capacity Utilization: Most manufacturing plants are operating near optimal capacity, with additional expansion planned in sterile injectables and radiopharma.
R&D Focus: Jubilant spent approximately 7 % of revenue on R&D, focusing on innovation in specialty formulations and biologics.
Regulatory Updates: The company continues to work closely with global regulators to ensure full compliance, with multiple sites under routine audit clearance.
💬 Management Commentary and Guidance
“We are pleased with the consistent performance across all key segments. Our investments in CDMO and Radiopharma are beginning to deliver results, and we expect stronger revenue and margin growth in the coming quarters,” said the Jubilant Pharmova management in their quarterly update.
Management Guidance Highlights:
FY 2025-26 revenue growth target: 10 – 12 % YoY
Margin improvement: Expected to reach 17 – 18 % by FY 2026
Capex plan: Around ₹ 1,200 – ₹ 1,300 crore for expansion in injectables, radiopharma, and R&D
Debt control: Maintain net-debt/EBITDA below 1.3 x
Focus: High-value product pipeline and sustainable growth in global markets
📈 Analyst and Market View
Brokerage houses remain cautiously optimistic about Jubilant Pharmova’s outlook.
Motilal Oswal maintains a “Buy” rating with a target price near ₹ 640, citing visibility in CDMO and Radiopharma growth.
ICICI Direct highlights the company’s improved operating efficiency and rising order backlog as positive indicators.
Market analysts also note that the next few quarters will be crucial to confirm whether investments translate into stronger margins.
On the stock market, Jubilant Pharmova shares have remained range-bound between ₹ 515 and ₹ 550, but analysts see upside potential as new projects come online.
🔭 Outlook and Future Strategy
Looking ahead, Jubilant Pharmova aims to position itself as a leading integrated pharma and CDMO partner globally. The focus areas include:
Strengthening its Radiopharma and Specialty Pharma portfolio
Expanding sterile injectable manufacturing capacity
Deepening R&D capabilities in biologics and drug discovery
Achieving sustainable double-digit growth while maintaining balance sheet strength
As the global healthcare ecosystem evolves, Jubilant’s diversified business model — combining manufacturing, innovation, and partnerships — provides a strong foundation for long-term performance.
🏁 Conclusion
Jubilant Pharmova’s Q2 FY 2025-26 results reflect a steady growth story powered by innovation, disciplined investments, and operational efficiency. While short-term profitability remains moderate due to heavy R&D and capex spending, the medium-term outlook is promising.
With consistent growth in Radiopharma, CDMO, and Discovery Services, and strategic expansion across key therapeutic areas, the company is well on track to achieve sustainable profitability and shareholder value.
